NCT02319005: A reported trial by Alnylam Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02319005 |
|---|---|
| Title | A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2014 |
| Completion date | March 30, 2017 |
| Required reporting date | March 30, 2018, midnight |
| Actual reporting date | March 27, 2018 |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |